ICU Medical, Inc. — FY2009 Form 10-K
Reporting period: Fiscal year ended December 31, 2009. The filing is an annual report, not a standalone fourth-quarter filing. Amounts below are in U.S. dollars unless stated otherwise.
Business context
ICU Medical develops and manufactures disposable medical devices, including needleless I.V. connectors, custom infusion and oncology sets, and critical-care products. Its CLAVE connector generated 37% of 2009 revenue; custom products contributed about 34%. Hospira remained its largest customer, representing 53% of worldwide revenue.
Financial performance and liquidity
| Metric | FY2009 | FY2008 |
|---|---|---|
| Total revenue | $231.5 million | $204.7 million |
| Gross profit / margin | $108.8 million / 47% | $89.8 million / 44% |
| Operating income | $38.0 million | $31.4 million |
| Net income | $26.6 million | $24.3 million |
| Diluted EPS | $1.77 | $1.67 |
| Cash from operations | $48.6 million | $30.2 million |
- Revenue rose 13%; net income rose 9%. Gross margin improved three percentage points, with management attributing two points to favorable exchange rates and the remainder to product mix and manufacturing efficiencies.
- SG&A increased to $68.2 million from $53.6 million, primarily due to legal costs, added personnel, and sales and marketing expenses. R&D fell to $2.6 million from $4.8 million.
- At year-end, cash and investment securities totaled $108.1 million, down from $129.2 million including restricted cash and long-term investments in 2008. Working capital was $174.2 million. The balance sheet lists no borrowings or debt; verify the full filing for any debt-like commitments.
- Inventory rose to $41.3 million from $17.9 million, reflecting the shift toward direct sales and the acquired critical-care inventory. Accounts receivable was $47.8 million, including 37% attributable to Hospira.
- Investing cash outflow was $35.2 million, including $29.4 million for the Hospira critical-care assets and $16.7 million of property and equipment purchases, partly offset by net investment-security sales. Financing cash outflow was $17.7 million, including $20.4 million of share repurchases.
Material changes and fourth-quarter results
- On August 31, 2009, ICU Medical acquired Hospira’s critical-care product-line commercial rights and physical assets for $29.4 million. ICU Medical assumed sales, marketing, customer contracting and distribution, with Hospira providing transitional distribution and light-manufacturing services.
- The acquisition shifted critical-care sales from Hospira to direct and distributor channels. Domestic distributor/direct sales rose 84% and international distributor/direct sales rose 59%; Hospira revenue declined 15%, partly because critical-care sales were no longer booked to Hospira after the transaction.
- Fourth-quarter revenue was $69.8 million versus $56.7 million a year earlier; net income was $7.4 million versus $9.0 million. The filing does not provide a clear explanation for the year-over-year fourth-quarter net-income decline in the quarterly table.
- Revenue mix shifted: medical product manufacturers contributed 50% of product revenue versus 67% in 2008, while domestic distributor/direct and international distributor/direct channels rose to 29% and 21%, respectively.
Outlook, risks and unusual items
- Management forecast 2010 gross margin of about 43%, SG&A at 27%–28% of revenue, and an effective tax rate of about 35%. It expected modest U.S. CLAVE growth and increased critical-care sales, but cautioned that these expectations were uncertain.
- Management estimated 2010 capital expenditures of $17 million–$20 million, including completion of the Slovakia plant, which it expected to become operational in the second half of 2010. It said existing cash, investments and expected operating cash flow should fund operations for the next 12 months.
- Key risks include customer concentration and dependence on Hospira; competition and potential CLAVE price erosion; patent expirations and litigation; regulatory compliance and product liability; manufacturing and labor exposure in Mexico; foreign-exchange and raw-material costs; and execution, permitting, cost-overrun and timing risks for the Slovakia plant.
- ICU Medical is pursuing patent-infringement claims against RyMed; the case remained pending. The company paid $5.5 million, including interest, in 2009 on an Alaris judgment previously recorded. Unrecognized tax benefits were $5.3 million. The Hospira purchase includes a right to require repurchase of up to $6.0 million of finished goods if specified inventory remains unsold by August 31, 2011.
- Auditors gave an unqualified opinion on the financial statements and internal control over financial reporting. Management also concluded disclosure controls and internal controls were effective at year-end.
Most important facts for investors to verify
- Whether the transition from Hospira-mediated critical-care sales to direct distribution preserves customers, pricing and margins, and how much revenue remains dependent on Hospira.
- Whether the elevated inventory and receivables convert to sales and cash, including the potential $6.0 million inventory repurchase exposure.
- Actual 2010 gross margin, SG&A and tax-rate performance against management’s forecasts, and the sustainability of 2009 margin gains.
- Slovakia plant completion, required approvals, final capital costs and resulting utilization; compare actual capital spending with the $17 million–$20 million estimate.
- Developments in the RyMed patent litigation, upcoming patent expirations, and any impact on CLAVE competition or pricing.